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Abstract: Breast cancer is the most common cancer among women worldwide. Every year, nearly 1.4 million new 
cases of breast cancer are diagnosed, and about 450.000 women die of the disease. Approximately 15-25% of 
breast cancer cases exhibit increased quantities of the trans-membrane receptor tyrosine kinase human epidermal 
growth factor receptor 2 (HER2) on the tumor cell surface. Previous studies showed that blockade of this HER2 pro-
to-oncogene with the antibody trastuzumab substantially improved the overall survival of patients with this aggres-
sive type of breast cancer. Recruitment of natural killer (NK) cells and subsequent induction of antibody-dependent 
cell-mediated cytotoxicity (ADCC) contributed to this beneficial effect. We hypothesized that antibody binding to 
HER2-positive breast cancer cells and thus ADCC might be further improved by synergistically applying two different 
HER2-specific antibodies, trastuzumab and pertuzumab. We found that tumor cell killing via ADCC was increased 
when the combination of trastuzumab, pertuzumab, and NK cells was applied to HER2-positive breast cancer cells, 
as compared to the extent of ADCC induced by a single antibody. Furthermore, a subset of CD44highCD24lowHER2low 
cells, which possessed characteristics of cancer stem cells, could be targeted more efficiently by the combination 
of two HER2-specific antibodies compared to the efficiency of one antibody. These in vitro results demonstrated the 
immunotherapeutic benefit achieved by the combined application of trastuzumab and pertuzumab. These findings 
are consistent with the positive results of the clinical studies, CLEOPATRA and NEOSPHERE, conducted with patients 
that had HER2-positive breast cancer. Compared to a single antibody treatment, the combined application of trastu-
zumab and pertuzumab showed a stronger ADCC effect and improved the targeting of breast cancer stem cells.
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Introduction
Human epidermal growth factor receptor-2 
(HER2/neu, or c-erbB2) is a proto-oncogene, 
which belongs to a family of four trans-mem-
brane receptor tyrosine kinases that mediate 
critical functions, like cell growth, differentia-
tion, and survival, in malignant and normal 
breast epithelial cells [1]. HER2 is often involved 
in facilitating the interaction between epider-
mal growth factor receptor (EGFR) or HER3 and 
their corresponding ligands. In addition to the 
homodimerization of HER2, the heterodimer-
ization of HER2 and HER3 or EGF can initiate 
oncogenic signaling [2-4].
Approximately 15%-25% of primary breast can-
cers overexpress the HER2 protein due to 
amplification in the HER2 gene. The overexpres-
sion of HER2 is associated with an aggressive 
clinical phenotype, increased disease recur-
rence, and an unfavorable prognosis [5]. Many 
of these negative effects of HER2 overexpres-
sion can be reversed by the application of 
monoclonal antibodies directed against the 
HER2 antigen. The humanized monoclonal anti-
body trastuzumab (Herceptin®, Genentech) is 
directed against the extracellular domain of 
HER2. It is administered for the treatment of 
patients with HER2-positive breast and gastric 
cancers. The antibody improves disease-free 
and overall survival in the adjuvant, metasta-
sized setting [6, 7]. When trastuzumab is used 
as a monotherapy, it causes tumor cell growth 
inhibition. In combination with chemotherapeu-
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tics, like cisplatin, carboplatin, docetaxel and 
ionizing radiation, trastuzumab has additive 
effects and yields improvements in terms of 
response duration and progression-free surviv-
al [8, 9].
In addition to blocking the HER2 receptor, 
trastuzumab also triggers a mechanism of cell-
mediated immunity. When trastuzumab (an 
IgG1-type antibody) binds to target cells that 
overexpress the HER2 antigen, effector cells, 
like natural killer (NK) cells, actively recognize 
these labeled tumor cells via the Fcγ-part of 
trastuzumab. The NK cells then induce tumor 
cell death through ‘‘antibody-dependent cell-
mediated cytotoxicity’’ (ADCC) [10-14]. The effi-
cacy of HER2-directed therapies is then further 
improved by the spontaneous activation of an 
adaptive anti-tumor immune response which 
was essential for tumor clearance in mice [15]. 
A new approach for the treatment of HER2-
positive breast cancer is the combined applica-
tion of two HER2-specific antibodies, trastu-
zumab and pertuzumab. Pertuzumab is a 
humanized monoclonal antibody that binds to 
HER2 near the center of domain II. This inhibits 
the dimerization of HER2 with other HER family 
members, thus blocking further signaling pro-
cesses that are associated with tumor growth 
and progression. The co-localization of two 
Figure 1. HER2 expression on CD44high CD24low breast cancer stem cells is low. HER2 expression was analyzed by 
FACS on CD44highCD24high and CD44highCD24low cells from (A) the HER2-positive breast cancer cell line BT-474 and (B) 
primary breast cancer cells from a pleural effusion from a patient with metastasized HER2-positive breast cancer. 
Left panels: Stainings for CD44 and CD24. Cells in the lower right quadrant were considered to be CD44highCD24low 
whereas the upper right quadrant demarks CD44highCD24high cells. HER2/neu-stainings for the respective subsets 
are shown on the right. Green curve: isotype control antibodies (10 µg/ml); red curve: HER2 expression on CD-
44highCD24low cells; blue curve: HER2 expression on CD44highCD24high cells (10 µg/ml). Isotype binding was similar 
for CD24high and CD24low cells. Values for specific fluorescence intensities (SFI) were obtained by dividing the median 
signal obtained with the specific antibody by the median signal obtained with the corresponding isotype control.
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HER2 antibodies on distinct epitopes of the 
HER2 extracellular domain provides more effi-
cient inhibition of tumor growth than one anti-
body alone [16, 17].
The NEOSPHERE phase II study investigated a 
novel regimen of applying the combination of 
pertuzumab and trastuzumab, compared to 
trastuzumab alone, plus chemotherapy 
(docetaxel) in the neoadjuvant setting in women 
with early-stage HER2-positive breast cancer. 
Their data demonstrated that in that setting 
the combination of trastuzumab and pertuzum-
ab improved complete remission of pathology 
in the breast by >1.5 times over that achieved 
with trastuzumab alone [18]. Based on the cru-
cial role of the immune system for a highly effi-
cient response to anti-HER2 antibodies [15], 
this may hint at an improved activation of innate 
and adaptive immune cells.
In preliminary studies, we have successfully 
demonstrated the importance of NK cell–medi-
ated ADCC for the in vitro function of trastu-
zumab. Moreover, we could provide evidence 
that a huge proportion of HER2-positive cells 
that had survived an ADCC challenge with NK 
cells and trastuzumab showed a “cancer stem 
cell-like” phenotype [19]. Cancer stem cells 
(CSC), also termed tumor-initiating or metasta-
sis-initiating cells, had been previously 
described in mammary cancer [20]. This rare 
subpopulation which is characterized by a 
CD44highCD24low phenotype, is held responsible 
for resistance against different therapeutic 
approaches and for late recurrence. Therefore, 
it has become a high priority to target CSCs 
with different therapeutic tools. In the present 
study, we investigated the new HER2-specific 
antibody, pertuzumab, and compared its activ-
ity to the combination of trastuzumab and per-




MCF-7, MDA-MB-231, BT-474, and SK-BR-3 
breast cancer cells were obtained from the 
American Type Culture Collection (Manassas, 
VA, USA) and cultured as indicated by the sup-
plier. Primary tumor cells were obtained from 
malignant pleural effusions of patients with 
metastasized HER2-overexpressing breast 
cancer. Further investigation of these cells was 
approved by both the patients and the local 
ethics committee. Cells were centrifuged, 
washed with PBS, and transferred to L-valine-
deficient Dulbecco’s Modified Eagle’s Medium, 
supplemented with D-valine, 2% FCS (Biochrom, 
Berlin, Germany), penicillin (100 IU/ml), strepto-
mycin (100 IU/ml), and 0.2% sodium pyruvate 
(all from PAA, Cölbe, Germany). Non-adherent 
cells were removed after 72 h by washing. 
Fibroblast growth was suppressed due to the 
lack of L-valine.
Flow cytometric analysis of surface expression 
levels and cell sorting
Cells were harvested with Accutase (PAA), 
blocked with 250 μg/ml human control IgG1 
(Beriglobin), and incubated with 5 μg/ml trastu-
zumab or 5 μg/ml pertuzumab (Genentech, 
Burlingame, CA, USA). Next, a Cy5-conjugated 
goat anti-human IgG (Rockland 
Immunochemicals, Gilbertsville, PA) detection 
antibody was added. Then, simultaneously, 
CD44-PE (Clone 2BJ18, BioLegend, San Diego, 
CA), CD24-FITC (clone SWA-11, kindly provided 
by Prof. Peter Altevogt, German Cancer 
Research Centre, Heidelberg), and the viability 
stain, 7-aminoactinomycin D (Sigma, 
Deisenhofen, Germany), were applied. Cells 
were analyzed on a FACSCalibur flow cytometer 
(BD Biosciences, Heidelberg, Germany). Where 
appropriate, expression levels are indicated as 
specific fluorescence intensity values, obtained 
by dividing the fluorescence intensity detected 
with the specific antibody by the signal mea-
sured with the isotype-matched control anti-
body. For fluorescence-activated cell sorting, 
the stained cells were separated twice with a 
Digital FACSVantage (BD Biosciences), first in 
yield mode, then in purity mode.
NK cell preparation and cytotoxicity assays 
Peripheral blood lymphocytes were obtained 
from healthy volunteers and isolated by density 
gradient centrifugation (Biocoll, Biochrom). 
Lymphocytes were cultured for 8 to 11 d with 
irradiated (30 Gy) RPMI 8866 feeder cells to 
obtain polyclonal NK cell populations. NK cell-
mediated lysis of tumor cells was assessed by 
a modified FATAL assay [21, 22]. Thus, NK cells 
were labeled with the eFluor® 670 Cell 
Proliferation Dye (ebioscience, Frankfurt, 
Germany), and target cells (200 000 per well) 
Synergistic ADCC by trastuzumab and pertuzumab
214 Am J Cancer Res 2013;3(2):211-220
were stained with carboxyfluorescein diacetate 
succinimidyl ester (Invitrogen, Karlsruhe, 
Germany). Cocultures were set up at different 
effector: target ratios, and lytic activity was 
assessed after 16 h by flow cytometric detec-
tion of carboxyfluorescein diacetate succinimi-
dyl ester (CFSE)dim cells among the eFluor 
670-negative target cell population. Values 
were corrected for spontaneous leakage of car-
boxyfluorescein diacetate succinimidyl ester.
Statistics
Experiments were performed at least three 
times with similar results and representative 
experiments are shown. Standard deviations 
for flow cytometry data were calculated using 
Summit software (Beckman Coulter, Krefeld, 
Germany). In Figure 3A, analysis of significance 
was performed using an unpaired, two-sided 
Student’s t-test.
Results and discussion
CD44highCD24low breast cancer cells show low 
HER2 surface expression
HER2 surface expression is known to be het-
erogeneous, even in HER2-positive breast can-
cer cell lines. Irrespective of the total amount of 
HER2, different HER2-positive breast cancer 
cell lines (SK-BR-3, BT-474, MDA-MB-231) were 
found to display significantly lower HER2 sur-
face expression levels on the CD44highCD24low 
Figure 2. The combination of trastuzumab and pertuzumab leads to increased antibody binding on tumor cells. 
HER2-specific antibody binding to HER2 positive breast cancer stem cells was quantified by flow cytometry of (A) BT-
474 cells and (B) cells from a malignant pleural effusion. Gating for CD44highCD24high and CD44highCD24low cells was 
performed as in Figure 1, Green curve: isotype control antiboy (10 µg/ml), red curve: trastuzumab (10 µg/ml); blue 
curve: pertuzumab (10 µg/ml); black curve: combined use of pertuzumab and trastuzumab (each 5 µg/ml). Please 
note that the data are plotted on a logarithmic scale.
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(presumed stem cell–like subset) cells than on 
more differentiated cells. A similar difference 
between stem cell-like and differentiated cells 
was observed in primary tumor cells from five 
patients with metastasized HER2-positive 
breast cancer, where the cancer cells were 
obtained from pleural effusions (Figure 1 and 
data not shown).
The combination of pertuzumab and trastu-
zumab increased antibody binding to the 
surface of HER2-positive tumor cells
Trastuzumab and pertuzumab bind to different 
epitopes of the HER2 protein (subdomains IV 
and II, respectively). We compared the amounts 
of trastuzumab, pertuzumab, or the combina-
tion of these HER2-specific antibodies that had 
bound to targets on tumor cells, SK-BR-3, 
BT-474, and MDA-MB-231, and to tumor cells 
from patients with metastasized, HER2-positive 
breast cancer that had exhibited pleural effu-
sions. We found that the combined application 
of trastuzumab and pertuzumab increased 
antibody binding to tumor cells compared to 
the separate application of trastuzumab or per-
tuzumab. Moreover, the combined application 
increased antibody binding to CD44high CD24low 
tumor stem cells, which showed low HER2 
expression about 40% (Figure 2 and data not 
shown).
Trastuzumab and pertuzumab enhanced NK-
cell-mediated killing (ADCC) of HER2-positive 
tumor cells
To assess the effect of trastuzumab and pertu-
zumab on NK cell-mediated lysis of HER2-
expressing breast cancer cells, we used a mod-
ified FATAL assay [22]. Target cell lysis was 
determined after 4 h of co-culture with poly-
clonal NK cells in the presence of trastuzumab, 
pertuzumab, or the combination of these two 
HER2-specific antibodies. The ratio of tumor 
cells to immune cells was 1:2. At high immune 
to tumor cell ratios, the tumor cells were killed 
independently of the ADCC effect. However, low 
immune to tumor cell ratios come closer to 
physiological conditions [23].
We found that both trastuzumab and pertuzum-
ab enhanced NK-cell-mediated killing of HER2-
positive tumor cells. The combined application 
of these HER2-specific antibodies in the killing 
assays significantly improved target cell lysis 
compared to the application of only one anti-
body; thus, antibody-mediated cytotoxicity was 
increased (Figure 3A). Considering the short 
time course of these experiments, the effects 
cannot be explained by growth inhibition.
Importantly, addition of HER2-specific antibod-
ies to the killing assay augmented tumor cell 
lysis only in tumor cell lines that overexpressed 
HER2. In HER2-negative cell lines, like 
HCC1806 or HCC1937, immune cell-mediated 
lysis could not be improved by the addition of 
trastuzumab, pertuzumab, or their 
combination.
Moreover, as in a previous series of experi-
ments (18), HER2-positive breast cancer cells 
surviving an ADCC challenge with NK cells and 
trastuzumab or pertuzumab showed an 
increased population of CD44highCD24lowHER2low 
tumor stem cells. This enrichment of treatment-
refractory CSCs could, however, be attenuated 
when the combination of both HER2-specific 
antibodies was employed. This suggests that 
the increased antibody binding to HER2low CSCs 
which is achieved by the combined use of 
trastuzumab and pertuzumab (see Figure 2) 
improves the immunotherapeutic targeting of 
these highly malignant cells during an interac-
tion with natural killer cells (Figure 3B). 
Trastuzumab and pertuzumab without NK cells 
had no effect on the CD24highCD24low popula-
tion, (data not shown).
Trastuzumab is approved for the treatment of 
early-stage breast cancer and metastatic 
breast cancers positive for HER2. It is further 
approved for application in combination with 
chemotherapeutic drugs. Trastuzumab has sig-
nificantly improved the overall survival of 
patients with HER2-positive breast cancer. 
However, even when the initial response to the 
drug is high, tumors can become drug-resistant 
or show reduced sensitivity, and patients expe-
rience relapse after treatment or disease pro-
gression. Thus, further development of HER2-
specific therapeutics is essential. In particular, 
pertuzumab is another promising therapeutic 
that specifically targets the HER2 antigen [8, 
24].
This study provided evidence that the combina-
tion of trastuzumab and pertuzumab increased 
total antibody binding to HER2-positive tumor 
cells in vitro. Thus, effects which are mediated 
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via the Fc portion of an antibody may be aug-
mented by synergistic application of two differ-
ent antibodies binding to different epitopes on 
the same antigen. Moreover, Fuentes et al. 
demonstrated a higher receptor affinity when 
both trastuzumab and pertuzumab were co-
localized on HER2 which further adds to the 
clinical synergism achieved with the combined 
application of these two antibodies. In particu-
lar, the subdomains I-III of the HER2 receptor 
became highly plastic in the presence of trastu-
zumab and showed increased association with 
pertuzumab [17].
We propose that both inhibition of signals that 
regulate cell proliferation, differentiation, and 
apoptosis, and elevated ADCC achieved by the 
combined binding likely contribute to the syn-
ergy shown between trastuzumab with pertu-
zumab [17, 25]. Consistent with this hypothe-
sis, the level of NK-cell-mediated ADCC was 
increased by adding a second HER2-specific 
antibody, particularly when the target cells 
expressed low to moderate levels of HER2 (i.e., 
when the available Fcγ receptors on NK cells 
were not saturated by the amount of anti-HER2 
antibody bound to the surface of the tumor 
cell). Given that HER2 expression is heteroge-
neous within a single tumor, additional antibody 
binding might be clinically relevant, particularly 
for malignancies that do not exhibit uniformly 
high expression of HER2.
Moreover, although a single antibody may suf-
ficiently liberate the full potential of ADCC 
effects in in vitro assays, antibody penetration 
may sometimes not be ideal in the tumor tis-
sue. Accordingly, the use of two different anti-
bodies with slightly different physico-chemical 
properties could be advantageous. Also steric 
constraints will often inhibit the optimal access 
of Fc-γ receptor-expressing cells to antibody-
loaded tumor cells in vivo [26]. In these cases, 
an additional number of immunoglobulins 
bound to tumor cells may improve ADCC by 
offering additional binding sites for Fc-γ-
receptors. In fact, we observed synergistic 
increases in ADCC with antibody concentra-
tions as low as 50 ng/ml; hence, this effect 
might be highly relevant in situations where 
antibody penetration is sub-optimal [27].
The importance of the ADCC effect for the anti-
tumor activity of trastuzumab was previously 
demonstrated by Clynes et al. They showed 
that the efficacy of trastuzumab was attenuat-
ed dramatically in knock-out mice that lacked 
activating FCgRIII receptors [28]. Incidentally, 
the importance of ADCC for the in vivo effect of 
the combination of trastuzumab and pertuzum-
ab was supported in a recent study [29] which 
showed that trastuzumab efficacy was 
improved in mouse models by stimulating 
CD137 on NK cells. Finally, ADCC-mediated 
activation of an innate immune response 
results in cytokine secretion and liberation of 
antigens which may enable the host to mount a 
potent adaptive immune response against 
tumor antigens [15]. Therefore, the ability to 
strengthen the anti-tumor immune response by 
increasing ADCC provides a further rationale 
for the combined administration of two HER2-
specific antibodies. Clearly, the available in vivo 
data do not reveal the precise mechanisms 
underlying the synergy observed with this com-
bination of HER2-directed antibodies. Thus, it 
remains unclear whether a beneficial effect 
depends more on the inhibition of HER2-
mediated signal transduction or whether the 
immune-mediated effect predominates. This 
may also be different for different tumors and 
for individual cancer patients with different 
Figure 3. Antibody-dependent NK cell killing and targeting of CD44highCD24low cancer stem cells is increased in the 
combined presence of trastuzumab and pertuzumab. A. Two HER2-positive breast cancer cell lines, BT-474 and SK-
BR-3, and the HER2-negative HCC1806 breast cancer cell line, were co-cultured with NK cells for 4 h, at a tumor-to 
NK cell ratio of 1:2. For better discrimination, immune cells were stained with eFluor® 670Cell Proliferation Dye and 
tumor cells were stained with CFSE. Target cell lysis of breast cancer cells (as evidenced by CFSE loss) was deter-
mined after 4 h by FACS analysis. Antibodies were used at 50ng/ml. Normal human IgGs served as control for the 
humanized antibodies trastuzumab and pertuzumab. Data analysis was performed using an unpaired, two-sided 
Student´s t-test. Results from three independent experiments were analyzed, (*p<0.05). B. HER2-positive SK-BR-3 
breast cancer cells were incubated for 16 h with NK cells at a tumor-to NK cell ratio of 1:2. Among the surviving (i.e. 
7-AAD-negative) cells, the CD24highCD24low population was analyzed by FACS immediately after NK cells had been 
removed by washing. The respective percentages of CD24highCD24low cells are indicated for the native SK-BR-3 popu-
lation (upper left) and for the SK-BR-3 population after incubation with NK cells (upper right), after incubation with 
NK cells in the presence of 50 ng/ml trastuzumab (lower left), and after incubation with NK cells in the presence of 
50 ng/ml trastuzumab and pertuzumab (lower right).
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immune status. Still, as long as the various 
mechanisms all work towards the elimination of 
HER2-positive tumor cells, the potential to act 
via different modes of action only increases the 
chance of a favorable outcome.
Importantly, immunotherapeutic targeting of 
CD44highCD24lowHER2low cancer stem cells was 
found to be poor with trastuzumab only [18] 
and might be improved with the combination of 
two antibodies. We showed that the level of 
antibody binding to this subpopulation of 
aggressive tumor cells was higher when tumor 
cells were incubated with trastuzumab and per-
tuzumab compared to binding with one anti-
body alone. It thus appears likely that the high-
er antibody load should make these cells more 
susceptible to immune attack.
Accordingly, the combined trastuzumab and 
pertuzumab treatment caused elevations in 
antibody binding in both differentiated tumor 
cells and stem cells; this observation was con-
firmed in different HER2-positive cell lines and 
in tumor cells isolated from pleural effusions of 
patients with metastasized HER2-positive 
breast cancer. The positive effect of the com-
bined application of trastuzumab and pertu-
zumab was also consistent with results from 
the CLEOPATRA clinical phase II and III study 
and from the NEOSPHERE study. 
In 2010, Genentech initiated a Phase III trial, 
called Marianne, to evaluate the combination 
of pertuzumab with the antibody-drug conju-
gate, T-DM1; T-DM1 comprises trastuzumab 
conjugated with the tubulin inhibitor, DM1. 
Based on results from the present study, a pos-
itive outcome for this trial arm appears likely.
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